ADC Therapeutics shares surge 13.48% intraday on positive LOTIS-5/7 trial updates and strategic financing amendment.

ADC Therapeutics surged 13.48% intraday following its Q4 2025 earnings report and operational updates. The company highlighted positive LOTIS-7 trial data (89.8% response rate), revised its HealthCare Royalty financing for greater flexibility, and reported a $261.3M cash runway through 2028. Management emphasized key catalysts, including LOTIS-5 topline data in Q2 2026 and potential regulatory approvals by mid-2027. Reduced operating costs (50% decline) and improved financials, including a narrower Q4 net loss ($6.4M vs. $30.7M in 2024), further bolstered investor confidence. The stock’s sharp rise aligned with optimism over clinical progress, cost efficiency, and long-term growth prospects.